Opportunity Information: Apply for PAR 16 262
Apply for PAR 16 262
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.855, 93.856,.
- This funding opportunity was created on May 17, 2016 and posted on May 17, 2016.
- Applicants must submit their applications by Jan 04, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01) funding opportunity (PAR-16-262) is a discretionary NIH research grant announcement focused on advancing longer-acting drug delivery approaches for HIV. Its central goal is to stimulate research and development that can move HIV therapeutics and prevention products beyond daily or very frequent dosing by using sustained-release strategies. The underlying aim is improved durability of drug levels, which can support more consistent protection or viral suppression and potentially reduce the adherence burden that often limits real-world effectiveness.
This FOA invites applications proposing sustained-release antiviral products for either HIV treatment or HIV prevention, and it explicitly allows multiple delivery routes and technology platforms. Proposed approaches can include oral sustained-release formulations, long-acting injections, implants, or direct delivery systems designed for HIV target mucosal tissues. The opportunity is structured around minimum duration expectations tied to the delivery method: oral sustained-release strategies for treatment are expected to provide at least one week of coverage, while non-oral sustained-release systems (such as injections, implants, or mucosal delivery approaches) are expected to provide at least monthly dosing for either prevention or treatment, meaning the system should maintain protective or therapeutic efficacy with dosing no more frequent than once per month.
The award mechanism is an NIH R01, indicating support for substantial, hypothesis-driven or product-oriented research projects with clear aims and a defined development path. While the announcement summary does not list an award ceiling or the expected number of awards, the R01 mechanism generally supports multi-year research programs and can accommodate interdisciplinary teams, which is often important for sustained-release antivirals that sit at the intersection of pharmacology, formulation science, biomedical engineering, materials science, and HIV clinical/preclinical research.
Eligibility is broad and includes many organization types that commonly participate in biomedical product development. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those specific nonprofit categories); for-profit organizations (including entities other than small businesses); small businesses; and additional applicants as clarified in the full announcement text. This breadth signals an intent to attract proposals from academic labs, research institutes, product developers, and collaborative academic-industry teams.
Administratively, the opportunity is sponsored by HHS through the NIH (listed as HHS-NIH11) and is associated with CFDA numbers 93.242, 93.855, and 93.856, reflecting NIH program areas relevant to infectious disease, biomedical research, and HIV/AIDS-related work. The FOA was created and posted on May 17, 2016, and the listed closing date for the opportunity was January 4, 2019. Overall, the announcement is geared toward building and validating sustained-release antiviral delivery systems capable of providing week-long oral treatment coverage or month-or-longer protection/efficacy for other delivery modalities, with the broader public health aim of strengthening HIV treatment and prevention options through longer-acting formulations.
FAQs: Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01) (PAR-16-262)
What is the SRATP (R01) funding opportunity (PAR-16-262)?
SRATP (R01) (PAR-16-262) is a discretionary NIH research grant opportunity focused on advancing sustained-release (longer-acting) drug delivery approaches for HIV treatment and HIV prevention.
What is the main goal of this FOA?
The central goal is to stimulate research and development of longer-acting antiviral delivery strategies that move HIV therapeutics and prevention products beyond daily or very frequent dosing by maintaining durable drug levels over time.
Why is NIH emphasizing sustained-release antivirals for HIV?
The FOA is aimed at improving the durability of drug levels to support more consistent protection or viral suppression and to reduce the adherence burden that can limit real-world effectiveness of HIV treatment and prevention.
Does this opportunity support HIV treatment, HIV prevention, or both?
Both. The FOA invites applications proposing sustained-release antiviral products for either HIV treatment or HIV prevention.
What types of drug delivery approaches are allowed?
The announcement explicitly allows multiple delivery routes and technology platforms. Examples mentioned include oral sustained-release formulations, long-acting injections, implants, and direct delivery systems designed for HIV target mucosal tissues.
Are oral sustained-release approaches allowed?
Yes. Oral sustained-release strategies are specifically included as an allowable approach.
Are long-acting injections and implants allowed?
Yes. Non-oral sustained-release systems such as injections and implants are explicitly listed as allowable approaches.
Does the FOA allow direct delivery to mucosal tissues?
Yes. The FOA includes direct delivery systems designed for HIV target mucosal tissues among the allowable approaches.
What minimum duration is expected for oral sustained-release strategies?
For oral sustained-release strategies intended for HIV treatment, the expectation is at least one week of coverage.
What minimum duration is expected for non-oral sustained-release systems?
For non-oral sustained-release systems (for example, injections, implants, or mucosal delivery approaches), the expectation is at least monthly dosing for either prevention or treatment, meaning dosing should be no more frequent than once per month while maintaining protective or therapeutic efficacy.
Does the monthly dosing expectation apply to both prevention and treatment?
Yes. The minimum expectation described for non-oral sustained-release systems is at least monthly dosing for either HIV prevention or HIV treatment.
What is the funding mechanism for SRATP?
The award mechanism is an NIH R01 research project grant.
What does using an R01 mechanism imply about the project type?
The R01 mechanism indicates support for substantial research projects with clear aims and a defined development path, and it can support hypothesis-driven or product-oriented work.
Does the FOA indicate an award ceiling or the expected number of awards?
No. The provided summary does not list an award ceiling or an expected number of awards.
Who is sponsoring this opportunity?
The opportunity is sponsored by HHS through the NIH (listed as HHS-NIH11).
What CFDA numbers are associated with this FOA?
The FOA is associated with CFDA numbers 93.242, 93.855, and 93.856.
When was this FOA created and posted?
The FOA was created and posted on May 17, 2016.
What is the listed closing date for this opportunity?
The listed closing date for the opportunity was January 4, 2019.
What types of organizations are eligible to apply?
Eligibility is broad. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those specific nonprofit categories); for-profit organizations (including entities other than small businesses); small businesses; and additional applicants as clarified in the full announcement text.
Are for-profit companies eligible to apply?
Yes. For-profit organizations are listed as eligible, including entities other than small businesses.
Are small businesses eligible to apply?
Yes. Small businesses are explicitly listed as eligible applicants.
Are universities and colleges eligible to apply?
Yes. Both public and state-controlled institutions of higher education and private institutions of higher education are listed as eligible.
Are nonprofit organizations eligible to apply?
Yes. Nonprofit organizations with or without 501(c)(3) status are included (with the noted exclusion of institutions of higher education within those specific nonprofit categories, as stated in the summary).
Are government entities eligible to apply?
Yes. State, county, and local governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities are listed among eligible applicants.
Are tribal governments and tribal organizations eligible to apply?
Yes. Federally recognized Native American tribal governments and other tribal organizations are included in the eligibility list.
Is this FOA intended only for academic research, or also for product development?
Based on the summary, it is intended for research and development of sustained-release antiviral delivery systems and can support product-oriented projects with clear aims and a defined development path.
What kinds of expertise or teams does this FOA seem to anticipate?
The summary notes that sustained-release antivirals often sit at the intersection of pharmacology, formulation science, biomedical engineering, materials science, and HIV clinical/preclinical research, and the R01 mechanism can accommodate interdisciplinary teams.
What public health impact is this FOA aiming for?
The broader aim described is to strengthen HIV treatment and prevention options through longer-acting formulations that could improve consistency of protection or viral suppression and reduce adherence burden.
Browse more opportunities from the same category: Health
Next opportunity: San Mateo Youth Engagement and Development
Previous opportunity: FY 2016 Training and Technical Assistance – Regional Training Conferences
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 262
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 262) also looked into and applied for these:
| Funding Opportunity |
|---|
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities Outside the United States Apply for CDC RFA IP16 1603 Funding Number: CDC RFA IP16 1603 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $400,000 |
| NHLBI Career Transition Award for Intramural Fellows (K22) Apply for PAR 16 267 Funding Number: PAR 16 267 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization Apply for CDC RFA IP16 1606 Funding Number: CDC RFA IP16 1606 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $2,000,000 |
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP16 1604 Funding Number: CDC RFA IP16 1604 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $250,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 16 269 Funding Number: PAR 16 269 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01) Apply for RFA AI 16 047 Funding Number: RFA AI 16 047 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03) Apply for PAR 16 268 Funding Number: PAR 16 268 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 16 270 Funding Number: PAR 16 270 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 16 272 Funding Number: PAR 16 272 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 16 271 Funding Number: PAR 16 271 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 17 008 Funding Number: HRSA 17 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) Apply for CDC RFA PS14 140204CONT17 Funding Number: CDC RFA PS14 140204CONT17 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| CDC’s National Undergraduate Student Program: A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110106CONT16 Funding Number: CDC RFA MN11 110106CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Fogarty Global Health Training Program (D43) Apply for RFA TW 16 002 Funding Number: RFA TW 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Surveillance, intervention, and referral to services activities for infants with microcephaly or other adverse outcomes linked with the Zika virus Apply for CDC RFA DD16 1605 Funding Number: CDC RFA DD16 1605 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $360,000 |
| Developing New Clinical Decision Support to Disseminate and Implement Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 282 Funding Number: PA 16 282 Agency: HHS-AHRQ Category: Health Funding Amount: $750,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Specialized Center Cooperative Agreements (U54) Apply for RFA OD 16 011 Funding Number: RFA OD 16 011 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Comprehensive Platform for Integrated Communication Initiative (CPICI) Apply for RFA 621 16 000003 Funding Number: RFA 621 16 000003 Agency: USAID-TAN Category: Health Funding Amount: $46,200,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Resource Cooperative Agreement (U42) Apply for RFA OD 16 012 Funding Number: RFA OD 16 012 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Scaling Established Clinical Decision Support to Facilitate the Dissemination and Implementation of Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 283 Funding Number: PA 16 283 Agency: HHS-AHRQ Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 262", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.